Abstract：【Objective】 To explore the relationship of the clinicopathological features and prognosis with the expression of cytokeratin 20 (CK20) and p53 in gastric cancer patients.【Methods】 Seventy patients who were diagnosed with gastric cancer for the first time and underwent gastric cancer resection were selected for the study. The levels of CK20 and p53 in the cancerous tissues and para-cancerous tissues of the patients were analyzed to investigate the association of the expression of the two with the clinicopathological features, further the effects of the two on the prognosis of the patients were analyzed by Cox.【Results】 The percentage of CK20 and p53 protein positivity in cancer tissues of gastric cancer patients was higher than that in para-cancerous tissues (P<0.05). The percentage of CK20 and p53 protein positive expression in cancer tissues of patients with stage Ⅲ, low differentiation, and lymph node metastasis was higher than that of patients with stage Ⅰ/Ⅱ, middle/high differentiation, and lymph nodes without metastasis (P<0.05). After 1 year of follow-up, 3 out of 70 patients were lost, and 15 out of the remaining 67 patients died, with a case-fatality rate of 22.39%(15/67).The results of Cox analysis showed that stage Ⅲ, poorly differentiated, lymph node metastasis, p53 protein positivity, and CK20 protein positivity were all influencing factors in the prognosis of patients with gastric cancer (P< 0.05).【Conclusion】 The expression levels of p53 and CK20 proteins in cancer tissues of gastric cancer patients showed a close correlation with the degree of differentiation of the tumor, the presence of lymph node metastasis, the clinical stage, and the prognosis of the patients.
田小豆, 张院院. CK20、p53表达与胃癌患者临床病理特征及预后的关系[J]. 医学临床研究, 2024, 41(12): 1864-1866.
TIAN Xiaodou, ZHANG Yuanyuan. Expression of CK20 and p53 and their Relationship with Clinicopathological Features and Prognosis in Gastric Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(12): 1864-1866.
[1] ALIPOUR M. Molecular mechanism of helicobacter pylori-induced gastric cancer[J].J Gastrointest Cancer,2021, 52(1):23-30. [2] KAWAZOE A, SHITARA K, BOKU N, et al. Current status of immunotherapy for advanced gastric cancer[J].Jpn J Clin Oncol,2021, 51(1):20-27. [3] 艾冬梅,王宝娟,乔秀真. 胃癌术后化疗前后检测外周血细胞角蛋白20mRNA的临床意义[J].中国临床研究,2019,29(7):927-929. [4] SAPIR T, SHIFTEH D, PAHMER M, et al. Protein arginine methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K pathways: a case for PRMT5 inhibition and combination therapies in cancer[J].Mol Cancer Res,2021, 19(3):388-394. [5] ITO M, TANAKA S, CHAYAMA K. Characteristics and early diagnosis of gastric cancer discovered after helicobacter pylori eradication[J].Gut Liver,2021,15(3):338-345. [6] USUI G, MATSUSAKA K, MANO Y, et al. DNA methylation and genetic aberrations in gastric cancer[J].Digestion,2021,102(1):25-32. [7] 徐星榕,白菊萍,边芸,等. CK、MUC5ac、Ki67表达与胃癌癌前病变的关系及对胃癌早期诊断的价值[J].国际检验医学杂志,2023,44(12):1522-1525. [8] MARTE G, TUFO A, STECCANELLA F, et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: a systematic review of the literature and meta-analysis of prognostic factors[J].J Clin Med,2021, 10(5):49-53. [9] BEKETOVA E, OWENS J L, ASBERRY A M, et al. PRMT5: a putative oncogene and therapeutic target in prostate cancer[J].Cancer Gene Ther,2022, 29(4):264-276. [10] FATTAHI S, AMJADI-MOHEB F, TABARIPOUR R, et al. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond[J].Life Sci,2020, 262(49):513-517. [11] YAHYAZADEH R, BASHASH D, GHAFFARI P, et al. Evaluation of hTERT, CK20, and survivin in urine for noninvasive detection of bladder cancer using real-time PCR[J].BMC Urol,2021,21(1):64. [12] XU Y, ZHANG P, TAN Y Z, et al. A potential panel of five mRNAs in urinary extracellular vesicles for the detection of bladder cancer[J].Transl Androl Urol,2021,10(2):809-820. [13] 朱晓燕,姚冬颖,郭军. p53、PVT1基因联合miRNA-92a检测在评估胃癌患者预后中的价值[J].国际检验医学杂志,2021,42(10):1266-1270. [14] SAMAL V, JIRASEK T, PALDUS V, et al. Urachal yolk sac tumor penetrating the bladder as a diagnostic challenge: a case report and review of the literature[J].Diagn Pathol,2022,17(1):8. [15] USUI G, MATSUSAKA K, MANO Y, et al. DNA methylation and genetic aberrations in gastric cancer[J].Digestion,2021,102(1):25-32.
2024, Vol. 41 
